Plasm Gastrin Concentrations in Response to Nexium Administration in Healthy Volunteers

Completed · Phase 1

Conditions studied: Healthy

In brief

This dose response study is proposed to explore the extent to which Nexium increases endogenous gastrin concentrations and to assess whether Nexium treatment may be useful in the setting of islet cell transplantation for type 1 diabetes to expand islet cells in vivo after transplant.

Key facts

Study ID

NCT01135472

Run by

City of Hope Medical Center

People needed

10

Starts

2010-03-01

Expected to finish

2012-04-01

Last updated by the study team

2012-12-18

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• age 18-65
• healthy
• free of clinical signs of diabetes, peptic ulcer, liver or kidney disease,autoimmune disease, or any acute chronic infection.

You may not qualify if…

• history or clinical signs of diabetes
• history of liver or kidney disease
• positive H-pylori status
• currently using a proton pump inhibitor
• prior hypersensitivity to Nexium
• pregnant or breastfeeding women

Where it is running

• City of Hope Medical Center — Duarte, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.